BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Niro GA, Smedile A, Ippolito AM, Ciancio A, Fontana R, Olivero A, Valvano MR, Abate ML, Gioffreda D, Caviglia GP, Rizzetto M, Andriulli A. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol. 2010;53:834-840. [PMID: 20800919 DOI: 10.1016/j.jhep.2010.06.008] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Caviglia GP, Ciancio A, Rizzetto M. A Review of HDV Infection. Viruses 2022;14:1749. [DOI: 10.3390/v14081749] [Reference Citation Analysis]
2 Zhang Z, Ni Y, Lempp FA, Walter L, Mutz P, Bartenschlager R, Urban S. Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.05.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Papatheodoridi A, Papatheodoridis G. Hepatocellular carcinoma: the virus or the liver? Liver Int 2022. [PMID: 35319167 DOI: 10.1111/liv.15253] [Reference Citation Analysis]
4 Brancaccio G, Shanyinde M, Puoti M, Gaeta GB, Monforte AD, Vergori A, Rusconi S, Mazzarelli A, Castagna A, Antinori A, Cozzi-lepri A. Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy. Pathogens and Global Health. [DOI: 10.1080/20477724.2022.2047551] [Reference Citation Analysis]
5 Lempp FA, Roggenbach I, Nkongolo S, Sakin V, Schlund F, Schnitzler P, Wedemeyer H, Le Gal F, Gordien E, Yurdaydin C, Urban S. A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection. Viruses 2021;13:2371. [PMID: 34960640 DOI: 10.3390/v13122371] [Reference Citation Analysis]
6 Bakkaloglu OK, Yildirim O, Cavus B, Evirgen S, Gokturk S, Ormeci A, Soyer O, Akyuz F, Demir K, Kaymakoglu S, Gulluoglu M, Karaca C. Can Interferon therapy change natural course of Hepatitis Delta infection, A clinical and pathological study. Antimicrob Agents Chemother 2021;:AAC0158621. [PMID: 34694876 DOI: 10.1128/AAC.01586-21] [Reference Citation Analysis]
7 Caviglia GP, Martini S, Ciancio A, Niro GA, Olivero A, Fontana R, Tandoi F, Rosso C, Romagnoli R, Saracco GM, Smedile A, Rizzetto M. The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease. J Adv Res 2021;33:183-7. [PMID: 34603788 DOI: 10.1016/j.jare.2021.02.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Scheller L, Hilgard G, Anastasiou O, Dittmer U, Kahraman A, Wedemeyer H, Deterding K. Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients. Medicine (Baltimore) 2021;100:e26571. [PMID: 34260535 DOI: 10.1097/MD.0000000000026571] [Reference Citation Analysis]
9 Kamal H, Fornes R, Simin J, Stål P, Duberg AS, Brusselaers N, Aleman S. Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies. J Viral Hepat 2021. [PMID: 34291520 DOI: 10.1111/jvh.13577] [Reference Citation Analysis]
10 Niro GA, Ferro A, Cicerchia F, Brascugli I, Durazzo M. Hepatitis delta virus: From infection to new therapeutic strategies. World J Gastroenterol 2021; 27(24): 3530-3542 [PMID: 34239267 DOI: 10.3748/wjg.v27.i24.3530] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Lee WC, Chen TK, Han HF, Lin YC, Hwang YM, Kao JH, Chen PJ, Liu CJ. Investigating the prevalence and clinical effects of hepatitis delta viral infection in Taiwan. J Microbiol Immunol Infect 2021:S1684-1182(21)00066-9. [PMID: 34162528 DOI: 10.1016/j.jmii.2021.03.014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Farci P, Niro GA, Zamboni F, Diaz G. Hepatitis D Virus and Hepatocellular Carcinoma. Viruses 2021;13:830. [PMID: 34064419 DOI: 10.3390/v13050830] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Tseligka ED, Clément S, Negro F. HDV Pathogenesis: Unravelling Ariadne's Thread. Viruses 2021;13:778. [PMID: 33924806 DOI: 10.3390/v13050778] [Reference Citation Analysis]
14 Péneau C, Zucman-Rossi J, Nault JC. Genomics of Viral Hepatitis-Associated Liver Tumors. J Clin Med 2021;10:1827. [PMID: 33922394 DOI: 10.3390/jcm10091827] [Reference Citation Analysis]
15 Zhang Z, Urban S. New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies. Journal of Hepatology 2021;74:686-99. [DOI: 10.1016/j.jhep.2020.11.032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
16 Sagnelli C, Sagnelli E, Russo A, Pisaturo M, Occhiello L, Coppola N. HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges. Life (Basel) 2021;11:169. [PMID: 33671730 DOI: 10.3390/life11020169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Rizzetto M, Hamid S, Negro F. The changing context of hepatitis D. J Hepatol. 2021;74:1200-1211. [PMID: 33484770 DOI: 10.1016/j.jhep.2021.01.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
18 Roulot D, Brichler S, Layese R, Benabdesselam Z, Zoulim F, Thibault V, Scholtes C, Roche B, Castelnau C, Poynard T, Chazouillères O, Ganne N, Fontaine H, Gournay J, Guyader D, Le Gal F, Nahon P, Roudot-thoraval F, Gordien E, Grangé J, Landman R, Hezode C, Riachi G, Lascoux-combe C, Loustaud-ratti V, Rosa I, Mathurin P, Nguyen-khac E, Causse X, Naveau S, Habersetzer F, Metivier S, Labadie H, Sellier P, Bottero J, de Ledinghen V, Alric L, Calès P, Goujard C, Cadranel J, Salmon D, Hillaire S. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. Journal of Hepatology 2020;73:1046-62. [DOI: 10.1016/j.jhep.2020.06.038] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
19 Kamal H, Westman G, Falconer K, Duberg AS, Weiland O, Haverinen S, Wejstål R, Carlsson T, Kampmann C, Larsson SB, Björkman P, Nystedt A, Cardell K, Svensson S, Stenmark S, Wedemeyer H, Aleman S. Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes. Hepatology 2020;72:1177-90. [PMID: 32145073 DOI: 10.1002/hep.31214] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
20 Hercun J, Koh C, Heller T. Hepatitis Delta. Gastroenterology Clinics of North America 2020;49:239-52. [DOI: 10.1016/j.gtc.2020.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP; HIDIT-II study team. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infect Dis 2019;19:275-86. [PMID: 30833068 DOI: 10.1016/S1473-3099(18)30663-7] [Cited by in Crossref: 49] [Cited by in F6Publishing: 18] [Article Influence: 24.5] [Reference Citation Analysis]
22 Sharafi H, Rezaee-zavareh MS, Miri SM, Alavian SM. Global Distribution of Hepatitis D Virus Genotypes: A Systematic Review. Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.102268] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Alfaiate D, Clément S, Gomes D, Goossens N, Negro F. Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. J Hepatol 2020;73:533-9. [PMID: 32151618 DOI: 10.1016/j.jhep.2020.02.030] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
24 Bockmann JH, Grube M, Hamed V, von Felden J, Landahl J, Wehmeyer M, Giersch K, Hall MT, Murray JM, Dandri M, Lüth S, Lohse AW, Lütgehetmann M, Schulze Zur Wiesch J. High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort. BMC Gastroenterol 2020;20:24. [PMID: 32000689 DOI: 10.1186/s12876-020-1168-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
25 Spaan M, Carey I, Bruce M, Shang D, Horner M, Dusheiko G, Agarwal K. Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1. J Hepatol. 2020;72:1097-1104. [PMID: 31981726 DOI: 10.1016/j.jhep.2019.12.028] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
26 Da BL, Surana P, Kleiner DE, Heller T, Koh C. The Delta-4 fibrosis score (D4FS): A novel fibrosis score in chronic hepatitis D. Antiviral Res 2020;174:104691. [PMID: 31837393 DOI: 10.1016/j.antiviral.2019.104691] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
27 Da BL, Surana P, Takyar V, Kleiner DE, Heller T, Koh C. Vibration-controlled transient elastography for the detection of cirrhosis in chronic hepatitis D infection. J Viral Hepat 2020;27:428-36. [PMID: 31742822 DOI: 10.1111/jvh.13235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
28 Gasmi A, Guenifi W, Ouyahia A, Rais M, Boukhrissa H, Hachani A, Mechakra S, Laouamri S, Touabti A, Lacheheb A. First study of hepatitis delta virus in Algeria: Seroprevalence and risk factors in Setif region (east of Algeria). S Afr J Infect Dis 2019;34:110. [PMID: 34485451 DOI: 10.4102/sajid.v34i1.110] [Reference Citation Analysis]
29 Brancaccio G, Gaeta GB. Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection. Int J Antimicrob Agents 2019;54:697-701. [PMID: 31541699 DOI: 10.1016/j.ijantimicag.2019.09.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Gilman C, Heller T, Koh C. Chronic hepatitis delta: A state-of-the-art review and new therapies. World J Gastroenterol 2019; 25(32): 4580-4597 [PMID: 31528088 DOI: 10.3748/wjg.v25.i32.4580] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
31 Da BL, Heller T, Koh C. Hepatitis D infection: from initial discovery to current investigational therapies. Gastroenterol Rep (Oxf) 2019;7:231-45. [PMID: 32477569 DOI: 10.1093/gastro/goz023] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Ganesan M, Krutik VM, Makarov E, Mathews S, Kharbanda KK, Poluektova LY, Casey CA, Osna NA. Acetaldehyde suppresses the display of HBV-MHC class I complexes on HBV-expressing hepatocytes. Am J Physiol Gastrointest Liver Physiol 2019;317:G127-40. [PMID: 31141391 DOI: 10.1152/ajpgi.00064.2019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
33 Puigvehí M, Moctezuma-Velázquez C, Villanueva A, Llovet JM. The oncogenic role of hepatitis delta virus in hepatocellular carcinoma. JHEP Rep 2019;1:120-30. [PMID: 32039360 DOI: 10.1016/j.jhepr.2019.05.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
34 D’amico G, Perricone G. Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter? Curr Hepatology Rep 2019;18:144-56. [DOI: 10.1007/s11901-019-00473-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Mentha N, Clément S, Negro F, Alfaiate D. A review on hepatitis D: From virology to new therapies. J Adv Res 2019;17:3-15. [PMID: 31193285 DOI: 10.1016/j.jare.2019.03.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
36 Brancaccio G, Fasano M, Grossi A, Santantonio TA, Gaeta GB. Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. Aliment Pharmacol Ther. 2019;49:1071-1076. [PMID: 30793345 DOI: 10.1111/apt.15188] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
37 Melo Da Silva E, Kay A, Lobato C, Muwonge R, Zoulim F, Brites C, Parana R, Trepo C. Non-F HBV/HDV-3 coinfection is associated with severe liver disease in Western Brazilian Amazon. J Med Virol 2019;91:1081-6. [PMID: 30695106 DOI: 10.1002/jmv.25411] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
38 Koh C, Heller T, Glenn JS. Pathogenesis of and New Therapies for Hepatitis D. Gastroenterology. 2019;156:461-476.e1. [PMID: 30342879 DOI: 10.1053/j.gastro.2018.09.058] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
39 Abdurakhmanov D, Yesmembetov K, Rozina T, Nikulkina E, Tanaschuk E. Liver-related mortality in hepatitis delta patients: Russian single centre experience. Digestive and Liver Disease 2018;50:867-8. [DOI: 10.1016/j.dld.2018.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Diaz G, Engle RE, Tice A, Melis M, Montenegro S, Rodriguez-Canales J, Hanson J, Emmert-Buck MR, Bock KW, Moore IN, Zamboni F, Govindarajan S, Kleiner DE, Farci P. Molecular Signature and Mechanisms of Hepatitis D Virus-Associated Hepatocellular Carcinoma. Mol Cancer Res. 2018;16:1406-1419. [PMID: 29858376 DOI: 10.1158/1541-7786.mcr-18-0012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
41 Escolà-Vergé L, Riveiro-Barciela M, Buti M. A Case Report of Hepatocellular Carcinoma 5 Years After HBsAg Loss in Chronic Hepatitis Delta: How Long Surveillance is Required? Ann Hepatol 2017;16:630-2. [PMID: 28611272 DOI: 10.5604/01.3001.0010.0314] [Reference Citation Analysis]
42 Wranke A, Pinheiro Borzacov LM, Parana R, Lobato C, Hamid S, Ceausu E, Dalekos GN, Rizzetto M, Turcanu A, Niro GA, Lubna F, Abbas M, Ingiliz P, Buti M, Ferenci P, Vanwolleghem T, Hayden T, Dashdorj N, Motoc A, Cornberg M, Abbas Z, Yurdaydin C, Manns MP, Wedemeyer H, Hardtke S; Hepatitis Delta International Network. Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). Liver Int. 2018;38:842-850. [PMID: 28963781 DOI: 10.1111/liv.13604] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 6.6] [Reference Citation Analysis]
43 Aberra H, Gordien E, Desalegn H, Berhe N, Medhin G, Mekasha B, Gundersen SG, Gerber A, Stene-Johansen K, Øverbø J, Johannessen A. Hepatitis delta virus infection in a large cohort of chronic hepatitis B patients in Ethiopia. Liver Int 2018;38:1000-9. [PMID: 28980394 DOI: 10.1111/liv.13607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
44 Elazar M, Koh C, Glenn JS. Hepatitis delta infection - Current and new treatment options. Best Pract Res Clin Gastroenterol 2017;31:321-7. [PMID: 28774414 DOI: 10.1016/j.bpg.2017.05.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
45 Soriano V, Sherman KE, Barreiro P. Hepatitis delta and HIV infection. AIDS 2017;31:875-84. [PMID: 28121714 DOI: 10.1097/QAD.0000000000001424] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 4.6] [Reference Citation Analysis]
46 Wranke A, Serrano BC, Heidrich B, Kirschner J, Bremer B, Lehmann P, Hardtke S, Deterding K, Port K, Westphal M, Manns MP, Cornberg M, Wedemeyer H. Antiviral treatment and liver-related complications in hepatitis delta. Hepatology 2017;65:414-25. [PMID: 27770553 DOI: 10.1002/hep.28876] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 11.4] [Reference Citation Analysis]
47 Bahcecioglu IH, Sahin A. Treatment of Delta Hepatitis: Today and in the Future - A review. Infectious Diseases 2017;49:241-50. [DOI: 10.1080/23744235.2016.1271998] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
48 Le Gal F, Dziri S, Gerber A, Alloui C, Ben Abdesselam Z, Roulot D, Brichler S, Gordien E. Performance Characteristics of a New Consensus Commercial Kit for Hepatitis D Virus RNA Viral Load Quantification. J Clin Microbiol 2017;55:431-41. [PMID: 27881614 DOI: 10.1128/JCM.02027-16] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
49 Shirvani-Dastgerdi E, Schwartz RE, Ploss A. Hepatocarcinogenesis associated with hepatitis B, delta and C viruses. Curr Opin Virol 2016;20:1-10. [PMID: 27504999 DOI: 10.1016/j.coviro.2016.07.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
50 Sureau C, Negro F. The hepatitis delta virus: Replication and pathogenesis. Journal of Hepatology 2016;64:S102-16. [DOI: 10.1016/j.jhep.2016.02.013] [Cited by in Crossref: 124] [Cited by in F6Publishing: 117] [Article Influence: 20.7] [Reference Citation Analysis]
51 Madejón A, Romero M, Hernández &, García-Sánchez A, Sánchez-Carrillo M, Olveira A, García-Samaniego J. Hepatitis B and D viruses replication interference: Influence of hepatitis B genotype. World J Gastroenterol 2016; 22(11): 3165-3174 [PMID: 27003993 DOI: 10.3748/wjg.v22.i11.3165] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
52 Italian Association for the Study of the Liver (AISF); Italian Association for the Study of the Liver AISF. AISF position paper on liver disease and pregnancy. Dig Liver Dis. 2016;48:120-137. [PMID: 26747754 DOI: 10.1016/j.dld.2015.11.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
53 Wranke A, Heidrich B, Hardtke S, Wedemeyer H. Current Management of HBV/HDV Coinfection and Future Perspectives. Curr Hepatology Rep 2015;14:284-92. [DOI: 10.1007/s11901-015-0280-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
54 Alfaiate D, Dény P, Durantel D. Hepatitis delta virus: From biological and medical aspects to current and investigational therapeutic options. Antiviral Research 2015;122:112-29. [DOI: 10.1016/j.antiviral.2015.08.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
55 Abbas Z, Soomro GB, Hassan SM, Luck NH. Clinical presentation of hepatitis D in Pakistani children. Eur J Gastroenterol Hepatol 2014;26:1098-103. [PMID: 25089545 DOI: 10.1097/MEG.0000000000000168] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
56 Keshvari M, Alavian SM, Aghaee B, Behnava B, Mahdavi M, Fesharaki MG, Sharafi H. Seroepidemiology and clinical features of hepatitis delta among HBsAg carriers: a study from Hepatitis Clinic of Iranian Blood Transfusion Organization. Transfus Med. 2014;24:411-417. [PMID: 25523297 DOI: 10.1111/tme.12163] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H; HIDIT-1 Study Group. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 2014;60:87-97. [PMID: 24585488 DOI: 10.1002/hep.27102] [Cited by in Crossref: 167] [Cited by in F6Publishing: 132] [Article Influence: 20.9] [Reference Citation Analysis]
58 Calle Serrano B, Großhennig A, Homs M, Heidrich B, Erhardt A, Deterding K, Jaroszewicz J, Bremer B, Koch A, Cornberg M, Manns MP, Buti M, Wedemeyer H. Development and evaluation of a baseline-event-anticipation score for hepatitis delta. J Viral Hepat 2014;21:e154-63. [PMID: 24673975 DOI: 10.1111/jvh.12251] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
59 Keshvari M, Alavian SM, Sharafi H, Karimi G, Gholami Fesharaki M. Interferon alpha-2b therapy in chronic hepatitis delta. Hepat Mon 2014;14:e15729. [PMID: 24744790 DOI: 10.5812/hepatmon.15729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
60 Botelho-Souza LF, dos Santos Ade O, Borzacov LM, Honda ER, Villalobos-Salcedo JM, Vieira DS. Development of a reverse transcription quantitative real-time PCR-based system for rapid detection and quantitation of hepatitis delta virus in the western Amazon region of Brazil. J Virol Methods 2014;197:19-24. [PMID: 24316446 DOI: 10.1016/j.jviromet.2013.11.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
61 Boyd A, Miailhes P, Brichler S, Scholtès C, Maylin S, Delaugerre C, Chevallier-Queyron P, Gordien E, Girard PM, Lacombe K. Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients. AIDS Res Hum Retroviruses 2013;29:1535-40. [PMID: 23972039 DOI: 10.1089/AID.2013.0008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
62 Sy BT, Ratsch BA, Toan NL, Song le H, Wollboldt C, Bryniok A, Nguyen HM, Luong HV, Velavan TP, Wedemeyer H, Kremsner PG, Bock CT. High prevalence and significance of hepatitis D virus infection among treatment-naïve HBsAg-positive patients in Northern Vietnam. PLoS One 2013;8:e78094. [PMID: 24205106 DOI: 10.1371/journal.pone.0078094] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
63 Ghamari S, Alavian SM, Rizzetto M, Olivero A, Smedile A, Khedive A, Alavian SE, Zolfaghari MR, Jazayeri SM. Prevalence of hepatitis delta virus (HDV) infection in chronic hepatitis B patients with unusual clinical pictures. Hepat Mon 2013;13:e6731. [PMID: 24098308 DOI: 10.5812/hepatmon.6731] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
64 Heidrich B, Manns MP, Wedemeyer H. Treatment options for hepatitis delta virus infection. Curr Infect Dis Rep. 2013;15:31-38. [PMID: 23242761 DOI: 10.1007/s11908-012-0307-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 5.2] [Reference Citation Analysis]
65 Kew MC. Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an update. J Viral Hepat. 2013;20:149-157. [PMID: 23383653 DOI: 10.1111/jvh.12043] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
66 Samiullah S, Bikharam D, Nasreen. Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response. World J Gastroenterol 2012; 18(40): 5793-5798 [PMID: 23155322 DOI: 10.3748/wjg.v18.i40.5793] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
67 Sagnelli E, Stroffolini T, Mele A, Imparato M, Sagnelli C, Coppola N, Almasio PL. Impact of comorbidities on the severity of chronic hepatitis B at presentation. World J Gastroenterol. 2012;18:1616-1621. [PMID: 22529690 DOI: 10.3748/wjg.v18.i14.1616.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Niro GA, Smedile A. Current concept in the pathophysiology of hepatitis delta infection. Curr Infect Dis Rep. 2012;14:9-14. [PMID: 22161240 DOI: 10.1007/s11908-011-0233-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
69 Heidrich B, C. Serrano B, Idilman R, Kabaçam G, Bremer B, Raupach R, Önder FO, Deterding K, Zacher BJ, Taranta A, Bozkaya H, Zachou K, Tillmann HL, Bozdayi AM, Manns MP, Yurdaydın C, Wedemeyer H. HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome. Liver Int 2012;32:1415-25. [DOI: 10.1111/j.1478-3231.2012.02831.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
70 Gulsun S, Tekin R, Bozkurt F. Treatment of chronic delta hepatitis: a nine-year retrospective analysis. Hepat Mon 2011;11:731-5. [PMID: 22235216 DOI: 10.5812/kowsar.1735143X.728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
71 Dastgerdi ES, Herbers U, Tacke F. Molecular and clinical aspects of hepatitis D virus infections. World J Virol 2012; 1(3): 71-78 [PMID: 24175212 DOI: 10.5501/wjv.v1.i3.71] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
72 Sagnelli E, Stroffolini T, Mele A, Imparato M, Sagnelli C, Coppola N, Almasio PL. Impact of comorbidities on the severity of chronic hepatitis B at presentation. World J Gastroenterol 2012; 18(14): 1616-1621 [PMID: 22529690 DOI: 10.3748/wjg.v18.i14.1616] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
73 European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-185. [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010] [Cited by in Crossref: 2167] [Cited by in F6Publishing: 2070] [Article Influence: 216.7] [Reference Citation Analysis]
74 Gulsun S, Tekin R, Bozkurt F. Treatment of Chronic Delta Hepatitis: A Nine-Year Retrospective Analysis. Hepat Mon 2011;11:731-5. [DOI: 10.5812/kowsar.1735143x.2462] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
75 Lutz HH, Trautwein C. Reviving pegylated interferon as a therapeutic agent for hepatitis D: no more room for nucleos(t)ides? Hepatology 2011;53:2131-3. [PMID: 21618261 DOI: 10.1002/hep.24311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]